Cover Image
市場調查報告書

動脈封閉設備:醫療設備的開發平台評估

Arteriotomy Closure Devices - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 333945
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
動脈封閉設備:醫療設備的開發平台評估 Arteriotomy Closure Devices - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年08月01日 內容資訊: 英文 79 Pages
簡介

本報告提供現在開發中的動脈封閉設備之開發中產品資訊調查分析,提供主要產品·計劃,主要企業,臨床實驗資訊,最近的趨勢等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 動脈封閉設備概要

第3章 開發中的產品

  • 動脈封閉設備 - 開發中產品:各開發階段
  • 動脈封閉設備 - 開發中產品:各市場區隔
  • 動脈封閉設備 - 開發中產品:各地區
  • 動脈封閉設備 - 開發中產品:各法規途徑
  • 動脈封閉設備 - 開發中產品:各核准時期 (預定)
  • 進行中的臨床實驗

第4章 動脈封閉設備:正在開發的開發中產品 (各企業)

  • 動脈封閉設備企業 - 開發中產品:各開發階段
  • 動脈封閉設備 - 開發中產品:各開發階段

第5章 動脈封閉設備企業與產品概要

  • Aporo Biomedical, Inc. (Inactive)
  • Boston Scientific Corp
  • CardioDex Ltd.
  • CloSys Corp
  • Cook Medical Inc
  • CPC of America Inc
  • Essential Medical Inc
  • Harvard University
  • Mayo Clinic US
  • ProMed, Inc.
  • Rex Medical LP
  • Sheba Medical Center
  • Terumo Corp
  • Transluminal Technologies LLC
  • University of Rochester
  • Vascular Closure Systems, Inc.
  • Vascular Solutions Inc
  • Vivasure Medical Ltd.

第6章 動脈封閉設備:最近的趨勢

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0385EPD

GlobalData's Medical Devices sector report, "Arteriotomy Closure Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Arteriotomy Closure Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Arteriotomy Closure Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Arteriotomy Closure Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Arteriotomy Closure Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Arteriotomy Closure Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 6

2 Introduction 7

  • 2.1 Arteriotomy Closure Devices Overview 7

3 Products under Development 8

  • 3.1 Arteriotomy Closure Devices - Pipeline Products by Stage of Development 8
  • 3.2 Arteriotomy Closure Devices - Pipeline Products by Segment 9
  • 3.3 Arteriotomy Closure Devices - Pipeline Products by Territory 10
  • 3.4 Arteriotomy Closure Devices - Pipeline Products by Regulatory Path 11
  • 3.5 Arteriotomy Closure Devices - Pipeline Products by Estimated Approval Date 12
  • 3.6 Arteriotomy Closure Devices - Ongoing Clinical Trials 13

4 Arteriotomy Closure Devices - Pipeline Products under Development by Companies 14

  • 4.1 Arteriotomy Closure Devices Companies - Pipeline Products by Stage of Development 14
  • 4.2 Arteriotomy Closure Devices - Pipeline Products by Stage of Development 15

5 Arteriotomy Closure Devices Companies and Product Overview 16

  • 5.1 Aporo Biomedical, Inc. (Inactive) Company Overview 16
    • 5.1.1 Aporo Biomedical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.2 Boston Scientific Corp Company Overview 17
    • 5.2.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.3 CardioDex Ltd. Company Overview 27
    • 5.3.1 CardioDex Ltd. Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.4 CloSys Corp Company Overview 28
    • 5.4.1 CloSys Corp Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.5 Cook Medical Inc Company Overview 29
    • 5.5.1 Cook Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.6 CPC of America Inc Company Overview 30
    • 5.6.1 CPC of America Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.7 Essential Medical Inc Company Overview 31
    • 5.7.1 Essential Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.8 Harvard University Company Overview 36
    • 5.8.1 Harvard University Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.9 Mayo Clinic US Company Overview 37
    • 5.9.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.10 ProMed, Inc. Company Overview 38
    • 5.10.1 ProMed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.11 Rex Medical LP Company Overview 39
    • 5.11.1 Rex Medical LP Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.12 Sheba Medical Center Company Overview 40
    • 5.12.1 Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.13 Terumo Corp Company Overview 41
    • 5.13.1 Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.14 Transluminal Technologies LLC Company Overview 42
    • 5.14.1 Transluminal Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.15 University of Rochester Company Overview 43
    • 5.15.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.16 Vascular Closure Systems, Inc. Company Overview 44
    • 5.16.1 Vascular Closure Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.17 Vascular Solutions Inc Company Overview 47
    • 5.17.1 Vascular Solutions Inc Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.18 Vivasure Medical Ltd. Company Overview 48
    • 5.18.1 Vivasure Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 48

6 Arteriotomy Closure Devices- Recent Developments 51

  • 6.1 May 12, 2017: Boston Scientific Announces Positive European Registry Results For WATCHMAN Left Atrial Appendage Closure Device 51
  • 6.2 May 10, 2017: Boston Scientific to Present Data On WATCHMAN Left Atrial Appendage System at EuroPCR 2017 51
  • 6.3 May 01, 2017: Cardinal Health Reports Third-quarter Results for Fiscal Year 2017 52
  • 6.4 Apr 18, 2017: Cardinal Health updates fiscal 2017 guidance; Provides early outlook for future fiscal years 53
  • 6.5 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech 54
  • 6.6 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia 54
  • 6.7 Feb 07, 2017: Cardinal Health Reports Second-quarter Results for Fiscal Year 2017 55
  • 6.8 Jan 30, 2017: Memorial City Cardiology Associates Among First to Offer Breakthrough Atrial Fibrillation Treatment 56
  • 6.9 Jan 09, 2017: Cardinal Health Reaches Settlement With West Virginia 57
  • 6.10 Dec 23, 2016: Cardinal Health Announces Civil Settlement with DOJ 57
  • 6.11 Dec 12, 2016: Essential Medical Announces the Successful Initiation of the U.S. MANTA Vascular Closure Device Trial With the First Patients Enrolled in TAVR and EVAR Cases 58
  • 6.12 Nov 07, 2016: Essential Medical Announces Successful Live Case at TCT 59
  • 6.13 Nov 02, 2016: Boston Scientific Announces Initial U.S. Commercial Performance Of The WATCHMAN Left Atrial Appendage Closure Device 59
  • 6.14 Oct 31, 2016: Cardinal Health Reports First-quarter Results for Fiscal Year 2017 60
  • 6.15 Oct 26, 2016: Vivasure Medical Appoints Robert Hance to Companys Board of Directors 61
  • 6.16 Oct 24, 2016: Boston Scientific announced key Presentations on WATCHMAN Left Atrial Appendage System at Transcatheter Cardiovascular Therapeutics 2016 62
  • 6.17 Oct 24, 2016: New study compares different approaches for stroke prevention in patients with non-valvular atrial fibrillation 63
  • 6.18 Oct 24, 2016: Vascular Solutions Reports Third Quarter Results 64
  • 6.19 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 67
  • 6.20 Oct 11, 2016: SentreHEART Announces First Clinical Use of the Eclipse Surgical Left Atrial Appendage Closure Device 68
  • 6.21 Sep 26, 2016: Jon Giacomin of Cardinal Health Elected Chairman of HDA Board of Directors 69
  • 6.22 Aug 31, 2016: Rose Medical Center among First Hospitals in Colorado Offering Alternative to Long-Term Warfarin Medication with Newly Approved WATCHMAN LAAC Implant 69
  • 6.23 Aug 31, 2016: Cook Medical Names Jean-Marc Creissel Vice President of Operations in Greater China 70
  • 6.24 Aug 08, 2016: InSeal Medical Announces CE Mark Approval for the InClosure Large Bore Vascular Closure Device 70
  • 6.25 Aug 02, 2016: Cardinal Health Reports Q4 And Fiscal 2016 Results, Provides Fiscal 2017 Outlook 71
  • 6.26 Aug 01, 2016: Essential Medical Announces FDA Approval to Begin a U.S. Clinical Trial for the X-Seal 6F Vascular Closure Device 73
  • 6.27 Jul 25, 2016: Vascular Solutions Reports Second Quarter Results 73

7 Appendix 76

  • 7.1 Methodology 76
  • 7.2 About GlobalData 79
  • 7.3 Contact Us 79
  • 7.4 Disclaimer 79

List of Tables

1.1 List of Tables

  • Table 1: Arteriotomy Closure Devices - Pipeline Products by Stage of Development 8
  • Table 2: Arteriotomy Closure Devices - Pipeline Products by Segment 9
  • Table 3: Arteriotomy Closure Devices - Pipeline Products by Territory 10
  • Table 4: Arteriotomy Closure Devices - Pipeline Products by Regulatory Path 11
  • Table 5: Arteriotomy Closure Devices - Pipeline Products by Estimated Approval Date 12
  • Table 6: Arteriotomy Closure Devices - Ongoing Clinical Trials 13
  • Table 7: Arteriotomy Closure Devices Companies - Pipeline Products by Stage of Development 14
  • Table 8: Arteriotomy Closure Devices - Pipeline Products by Stage of Development 15
  • Table 9: Aporo Biomedical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 16
  • Table 10: Femoral Artery Closure Device - Product Status 16
  • Table 11: Femoral Artery Closure Device - Product Description 16
  • Table 12: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 17
  • Table 13: WATCHMAN Left Atrial Appendage System - Product Status 17
  • Table 14: WATCHMAN Left Atrial Appendage System - Product Description 18
  • Table 15: Boston Scientific Corp - Ongoing Clinical Trials Overview 19
  • Table 16: WATCHMAN Left Atrial Appendage System - A Prospective, Multi-center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device with Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation 21
  • Table 17: WATCHMAN Left Atrial Appendage System - AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial 21
  • Table 18: WATCHMAN Left Atrial Appendage System - Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation: ASAP-TOO 21
  • Table 19: WATCHMAN Left Atrial Appendage System - China Registry of WATCHMAN Left Atrial Appendage Closure for Non-valvular Atrial Fibrillation 22
  • Table 20: WATCHMAN Left Atrial Appendage System - Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage 22
  • Table 21: WATCHMAN Left Atrial Appendage System - Comparison of Safety and Efficacy of Left Atrial Appendage Occlusion Devices 22
  • Table 22: WATCHMAN Left Atrial Appendage System - Continued Access To PREVAIL (CAP2)- Watchman Left Atrial Appendage (LAA) Closure Technology 23
  • Table 23: WATCHMAN Left Atrial Appendage System - Interventional Left Atrial Appendage Closure Vs. Novel Anticoagulation Agents in High-risk Patients with Atrial Fibrillation (PRAGUE-17 Study) 23
  • Table 24: WATCHMAN Left Atrial Appendage System - Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent Percutaneous Coronary Intervention 23
  • Table 25: WATCHMAN Left Atrial Appendage System - Long Term Clinical Outcomes of Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation: From Korean Multicenter Registry 24
  • Table 26: WATCHMAN Left Atrial Appendage System - Registry on WATCHMAN Outcomes in Real-life Utilization 24
  • Table 27: WATCHMAN Left Atrial Appendage System - Registry on WATCHMAN Outcomes in Real-Life Utilization WASP Registry 24
  • Table 28: WATCHMAN Left Atrial Appendage System - The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial 25
  • Table 29: WATCHMAN Left Atrial Appendage System - The Strategy to Prevent Hemorrhage Associated with Anticoagulation in Renal Disease Management (STOP HARM) Trial 25
  • Table 30: WATCHMAN Left Atrial Appendage System - Watch Bleeding Episodes after Left Atrial Appendage Occlusion Versus Usual Care in Patients with Atrial FIBrillatIon and Severe to end-stage Chronic Kidney Disease (WatchAFIB in CKD) 25
  • Table 31: WATCHMAN Left Atrial Appendage System - WATCHMAN for Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement 26
  • Table 32: CardioDex Ltd. Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 33: EpiClose Plus - Product Status 27
  • Table 34: EpiClose Plus - Product Description 27
  • Table 35: CloSys Corp Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 36: CloSys HD - Product Status 28
  • Table 37: CloSys HD - Product Description 28
  • Table 38: Cook Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 39: X-Port Vascular Access Closure Device - Product Status 29
  • Table 40: X-Port Vascular Access Closure Device - Product Description 29
  • Table 41: CPC of America Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 42: MedClose - Product Status 30
  • Table 43: MedClose - Product Description 30
  • Table 44: Essential Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 45: MANTA - Product Status 31
  • Table 46: MANTA - Product Description 31
  • Table 47: X-Seal - Product Status 32
  • Table 48: X-Seal - Product Description 32
  • Table 49: Essential Medical Inc - Ongoing Clinical Trials Overview 33
  • Table 50: X-Seal - US Clinical Trial for the X-Seal 6F Vascular Closure Device 34
  • Table 51: MANTA - Pivotal Clinical Study to Evaluate the Safety and Effectiveness of MANTA Vascular Closure Device 35
  • Table 52: Harvard University Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 53: Access-Closure Device - Product Status 36
  • Table 54: Access-Closure Device - Product Description 36
  • Table 55: Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 56: Left Atrial Appendage Closure Device - Product Status 37
  • Table 57: Left Atrial Appendage Closure Device - Product Description 37
  • Table 58: ProMed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 59: Large Hole Closure Device - Product Status 38
  • Table 60: Large Hole Closure Device - Product Description 38
  • Table 61: Rex Medical LP Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 62: Auto-Close Vascular Sealing System - Product Status 39
  • Table 63: Auto-Close Vascular Sealing System - Product Description 39
  • Table 64: Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 65: Left Atrial Appendage Intraatrial Transcatheter Sutureless Closure - Product Status 40
  • Table 66: Left Atrial Appendage Intraatrial Transcatheter Sutureless Closure - Product Description 40
  • Table 67: Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 68: Vascular Closure Device - Product Status 41
  • Table 69: Vascular Closure Device - Product Description 41
  • Table 70: Transluminal Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 71: Velox CD - Product Status 42
  • Table 72: Velox CD - Product Description 42
  • Table 73: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 74: Vascular Closure Device - Product Status 43
  • Table 75: Vascular Closure Device - Product Description 43
  • Table 76: Vascular Closure Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 77: FastSeal Bioabsorbable Vascular Access Closure System - Product Status 44
  • Table 78: FastSeal Bioabsorbable Vascular Access Closure System - Product Description 44
  • Table 79: FastSeal Self - Closing Nitinol Clip System - Product Status 45
  • Table 80: FastSeal Self - Closing Nitinol Clip System - Product Description 45
  • Table 81: FastSeal Swellable And Bioabsorbable Tubular Plug System - Product Status 45
  • Table 82: FastSeal Swellable And Bioabsorbable Tubular Plug System - Product Description 46
  • Table 83: Vascular Solutions Inc Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 84: Magna Seal - Product Status 47
  • Table 85: Magna Seal - Product Description 47
  • Table 86: Vivasure Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 87: PerQseal - Product Status 48
  • Table 88: PerQseal - Product Description 48
  • Table 89: Vivasure Medical Ltd. - Ongoing Clinical Trials Overview 49
  • Table 90: PerQseal - Clinical Investigation Plan (CIP) for Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER III Study 50
  • Table 91: PerQseal - Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER II Study 50
  • Table 92: Glossary 78

List of Figures

1.2 List of Figures

  • Figure 1: Arteriotomy Closure Devices - Pipeline Products by Stage of Development 8
  • Figure 2: Arteriotomy Closure Devices - Pipeline Products by Segment 9
  • Figure 3: Arteriotomy Closure Devices - Pipeline Products by Territory 10
  • Figure 4: Arteriotomy Closure Devices - Pipeline Products by Regulatory Path 11
  • Figure 5: Arteriotomy Closure Devices - Pipeline Products by Estimated Approval Date 12
  • Figure 6: Arteriotomy Closure Devices - Ongoing Clinical Trials 13
Back to Top